Abstract: Deferasirox (ICL670, Exjade) is an orally active, lipophilic tridentate iron chelator primarily utilized for the management of transfusional iron overload. Recently, its therapeutic potential has expanded into the realms of ferroptosis and ischemia-reperfusion injury. Ferroptosis is a distinct, iron-dependent form of nonapoptotic programmed cell death driven by the accumulation of lipid peroxides. By effectively sequestering intracellular catalytic iron, deferasirox prevents the Fenton reaction, thereby mitigating reactive oxygen species (ROS) generation and subsequent lipid peroxidation. Beyond its iron-depleting capabilities, deferasirox exhibits significant anti-inflammatory, anti-fibrotic, and anti-tumor activities by modulating key cellular signaling pathways, including NF-κB, Wnt/β-catenin, and autophagy networks. Despite its clinical efficacy, the use of deferasirox is constrained by adverse effects such as renal toxicity, gastrointestinal disturbances, and specific mitochondrial toxicities that can lead to intestinal perforation. Furthermore, its limited ability to cross the blood-brain barrier restricts its application in neurodegenerative diseases. Future research directions emphasize the development of deferasirox-based nanochelators, synergistic combination therapies, and personalized medicine approaches to optimize its efficacy and safety profile in treating ferroptosis-driven pathologies and ischemia-reperfusion injuries.
1. Introduction
Iron is a crucial element for mammalian cells, playing a vital role in numerous physiological processes, including oxygen transport, DNA synthesis, and cellular metabolism [2]. However, iron homeostasis must be finely regulated, as excess labile iron is highly toxic. Unbound iron catalyzes the Fenton reaction, generating lethal reactive oxygen species (ROS) that cause severe oxidative damage to lipids, proteins, and nucleic acids [2][3]. This iron-mediated oxidative stress is a primary driver of ferroptosis, a recently identified form of regulated, nonapoptotic cell death characterized by iron-dependent lipid peroxidation of polyunsaturated fatty acid (PUFA)-rich cell membranes [1][2].
Ferroptosis has been implicated in the pathogenesis of numerous conditions, including ischemia-reperfusion injury, cardiovascular diseases, stroke, acute kidney disease, and severe infections such as COVID-19 [1][3]. To combat iron toxicity, iron chelation therapy has emerged as a critical therapeutic strategy. Deferasirox (ICL670, marketed as Exjade) is an FDA-approved, once-daily oral iron chelator traditionally used to treat chronic iron overload in conditions like β-thalassemia and myelodysplastic syndromes [2][5]. Recently, the ability of deferasirox to deplete intracellular iron and inhibit ferroptosis has positioned it as a promising candidate for mitigating ischemia-reperfusion injury and other ferroptosis-related inflammatory and neoplastic diseases [3].
2. Pharmacological Activity
The primary pharmacological activity of deferasirox is the reduction of systemic and intracellular iron burden, which is clinically monitored via serum ferritin levels and transferrin saturation [12]. By reducing iron accumulation, deferasirox effectively inhibits ferroptosis, preventing the extensive cellular damage and multiorgan dysfunction seen in conditions like COVID-19 and ischemic stroke [3].
Beyond simple iron removal, deferasirox exhibits potent anti-inflammatory and anti-fibrotic properties. In models of liver fibrosis, deferasirox counteracts inflammation by reducing the levels of inflammatory mediators such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and inducible nitric oxide synthase (iNOS), while also inhibiting the proliferation of hepatic stellate cells [2]. Furthermore, deferasirox has been shown to improve bone density and counteract osteoporosis in iron-overloaded patients by decreasing osteoclast overactivity [2][7].
In oncology, deferasirox demonstrates significant anti-tumor activity. It reduces the chemoresistance of cancer stem cells and synergizes with chemotherapy in treating various malignancies, including triple-negative breast cancer, esophageal cancer, and leukemia [8]. It inhibits the proliferation and invasion of pancreatic cancer cells and induces cell cycle arrest in the S phase, leading to apoptosis at higher concentrations [8].
3. Molecular Mechanism of Action
Deferasirox exerts its protective effects against ferroptosis and ischemia-reperfusion injury primarily by sequestering catalytic iron, thereby halting the Fenton reaction and preventing the formation of toxic lipid peroxides [3]. At the molecular signaling level, deferasirox modulates several critical pathways:
Inflammatory Signaling: Deferasirox inhibits the activation of the NF-κB pathway. It specifically downregulates the expression of NF-κB target genes involved in the inflammatory response, such as interleukin 1 receptor type 1 (IL1R1) and Toll-like Receptor 4 (TLR4) [2].
Wnt/β-catenin Pathway: Iron regulates Wnt signaling, and excess iron can cause abnormal Wnt/β-catenin upregulation, which enhances inflammatory processes. Deferasirox normalizes this signaling, which has shown benefits in neuro-inflammatory conditions like posthemorrhagic chronic hydrocephalus [2]. Conversely, in bone remodeling, deferasirox induces Wnt5a expression through the PI3K and NFAT pathways, reversing the negative effects of iron overload on osteoblast differentiation [7].
Autophagy and Ferritin Degradation: Deferasirox influences cellular autophagy. In multiple myeloma cells, it induces autophagy by markedly increasing LC3-II expression and suppressing the mTORC1 substrate p70S6 kinase, a negative regulator of autophagy [9]. Interestingly, while some chelators direct ferritin degradation through lysosomes, the lipophilic nature of deferasirox diverts ferritin degradation towards the proteasomal pathway [9].
Cancer Signaling: In neoplastic cells, deferasirox downregulates transforming growth factor-β1 (TGF-β1) and reduces the activation of Cdc42 and Rac1, which are critical for cancer cell invasion [8].
4. Structure-Activity Relationship (SAR)
The chemical name for deferasirox is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid [4]. It is a synthetic, tridentate iron chelator, meaning that two molecules of deferasirox are required to bind and form a stable complex with a single ferric (Fe3+) ion [5]. At a physiological pH of 7.4, both the free chelator and its iron complex carry a negative charge [6].
A defining feature of deferasirox is its high lipophilicity, possessing a partition coefficient (n-octanol/water) of 6.3 [6]. This lipophilic nature allows the active molecule (ICL670) to easily permeate cell membranes to access intracellular iron pools, providing a significant advantage over older, hydrophilic chelators like deferoxamine [9]. Furthermore, deferasirox binds firmly to plasma proteins, particularly albumin, which contributes to its long elimination half-life of 8 to 16 hours. This pharmacokinetic profile enables a convenient once-daily oral dosing regimen that provides 24-hour chelating coverage [5]. The drug and its iron complex are primarily metabolized via glucuronidation and cleared through the fecal route [6].
5. Current Limitations
Despite its efficacy, the clinical utility of deferasirox is limited by several adverse effects and pharmacokinetic barriers. Common side effects include gastrointestinal disturbances, skin rashes, and auditory toxicities [3]. Renal toxicity is a significant concern; deferasirox treatment has been associated with elevated serum creatinine levels, tubular dysfunction, and Fanconi syndrome [5][8].
At the cellular level, deferasirox causes severe mitochondrial swelling without depolarization, an effect attributed to a specific alteration in inner mitochondrial membrane permeability [8]. In critically ill patients, such as those with severe COVID-19, chronic use of deferasirox has been linked to intestinal inflammation and bowel perforation driven by this mitochondrial swelling and rapid viral replication in the gastrointestinal epithelium [3].
Furthermore, while deferasirox is highly membrane-permeable in peripheral tissues, it does not easily pass through the blood-brain barrier (BBB) [4]. This poor CNS penetrance limits its effectiveness in treating neurodegenerative diseases and ischemia-reperfusion injuries localized in the brain (e.g., ischemic stroke) compared to other chelators [4].
6. Future Perspectives
The proposed use of iron chelators for modulating ferroptosis signifies a new era in the design of therapeutic strategies for ischemia-reperfusion injury, cardiovascular diseases, and severe infections [1]. To overcome the current limitations of deferasirox, several future directions are being explored:
Nanomedicine: The development of DFX-based iron nanochelators and star-like polyethylene glycol-deferasirox conjugates aims to improve targeted delivery, enhance efficacy, and reduce systemic toxicity [3][10].
Combination Therapies: Synergistic chelation combinations are being investigated to optimize iron mobilization. For instance, combining deferasirox with deferoxamine (DFOA) or other agents may facilitate better brain-to-blood mobilization of toxic metals [11]. In oncology, combining deferasirox with standard chemotherapeutics or monoclonal antibodies shows promise in overcoming tumor drug resistance [3][8].
Personalized Medicine: The introduction of artificial intelligence to guide optimal chelation outcomes based on personalized medicine characteristics (ADMET, multi-omics) is expected to increase the impact of deferasirox [1]. Additionally, recognizing sex and gender differences in iron metabolism and chelation pharmacokinetics will be crucial for tailoring safe and effective dosing regimens in the future [5].
